Mechanistically, celecoxib efficiently inhibited Akt/mTORC1 signalling in hydrodynamically AKT‐injected mice and in vitro, subsequently suppressing the lipogenic pathway that potentiates lipid metabolic reprogramming in NAFLD. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.